Request availability and a quotation for your required quantity and destination.
| Product | Minoxidil 5 mg + Dutasteride 0.5 mg - Minwin D |
|---|---|
| Categories | Hair Care |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Product category: Hair Care
Minwin D is listed as a combination oral tablet containing minoxidil 5 mg and dutasteride 0.5 mg. Its hair-loss use and this fixed-dose combination are not FDA-approved. This is not a standard starting treatment and should only be considered with specialist supervision.
Minoxidil is a systemic blood-pressure-lowering vasodilator and may promote hair growth as an off-label effect. Dutasteride reduces conversion of testosterone to dihydrotestosterone (DHT). Neither mechanism makes this combination suitable for every person with hair loss.
Oral minoxidil has an FDA boxed warning for serious cardiovascular complications including pericardial effusion and worsening angina. Dutasteride may cause sexual adverse effects, affect PSA interpretation, and poses fetal risks if capsules or leaked contents are handled during pregnancy.
Chest pain, shortness of breath, sudden swelling, fainting or severe palpitations require urgent care. Discuss mood changes, breast symptoms and fertility concerns with a healthcare professional.
Tugain 5 topical minoxidil · Avodart dutasteride. These are distinct treatments, not interchangeable products.
DailyMed: oral minoxidil boxed warning
It is marketed for hair loss, but its fixed-dose combination is not FDA-approved for that indication.
It should not be treated as a standard starting option; specialist risk assessment is essential.
Yes. Oral minoxidil is a potent vasodilator with serious cardiovascular warnings.
Yes, it inhibits two forms of 5-alpha-reductase, lowering DHT.
Any response generally takes months and is not guaranteed.
Dutasteride may cause reduced libido, erectile or ejaculation problems.
Dutasteride has important pregnancy risks and this combination is not an established approved hair-loss treatment for women.
Not without a clinician assessing cumulative exposure and adverse effects.
Chest pain, difficulty breathing, fainting, or severe fluid retention require prompt medical evaluation.
If prescribed, discuss discontinuation with the clinician, particularly because oral minoxidil affects blood pressure.
Cureiva provides educational product information and handles lawful enquiries subject to prescriptions, product verification and destination-country rules. This is not individual medical advice or a claim of clinician sign-off. Updated October 2026.